Leukocyte cell-derived chemotaxin 2 is an antiviral regulator acting through the proto-oncogene MET.
Takayoshi ShirasakiSatoshi YamagoeTetsuro ShimakamiKazuhisa MuraiRyu ImamuraKiyo-Aki IshiiHiroaki TakayamaYukako MatsumotoNatsumi Tajima-ShirasakiNaoto NagataRyogo ShimizuSouma YamanakaAtsushi AbeHitoshi OmuraKazunori KawaguchiHikari OkadaTaro YamashitaTomoki YoshikawaKazuhiro TakimotoMotoko TaharaguchiShogo TakatsukaYoshitsugu MiyazakiToshikatsu TamaiYamato TanabeMakoto KurachiYasuhiko YamamotoShuichi KanekoKunio MatsumotoToshinari TakamuraMasao HondaPublished in: Nature communications (2022)
Retinoic acid-inducible gene (RIG)-I is an essential innate immune sensor that recognises pathogen RNAs and induces interferon (IFN) production. However, little is known about how host proteins regulate RIG-I activation. Here, we show that leukocyte cell-derived chemotaxin 2 (LECT2), a hepatokine and ligand of the MET receptor tyrosine kinase is an antiviral regulator that promotes the RIG-I-mediated innate immune response. Upon binding to MET, LECT2 induces the recruitment of the phosphatase PTP4A1 to MET and facilitates the dissociation and dephosphorylation of phosphorylated SHP2 from MET, thereby protecting RIG-I from SHP2/c-Cbl-mediated degradation. In vivo, LECT2 overexpression enhances RIG-I-dependent IFN production and inhibits lymphocytic choriomeningitis virus (LCMV) replication in the liver, whereas these changes are reversed in LECT2 knockout mice. Forced suppression of MET abolishes IFN production and antiviral activity in vitro and in vivo. Interestingly, hepatocyte growth factor (HGF), an original MET ligand, inhibits LECT2-mediated anti-viral signalling; conversely, LECT2-MET signalling competes with HGF-MET signalling. Our findings reveal previously unrecognized crosstalk between MET-mediated proliferation and innate immunity and suggest that targeting LECT2 may have therapeutic value in infectious diseases and cancer.